+A -A

Tabela:
Comparative View:

4Q18 Create chart
Net sales revenues 1,263,377
Change in Fair Value of Biological Assets 27,201
Cost of Goods Sold -859,665
Depreciation / Amortization / exhaustion -104,142
Exhaustion of biological assets -39,805
Gross Profit 286,966
Selling Expenses -190,806
General and Administrative Expenses -52,079
Management Compensation -4,100
Other Operating Compensation -278,619
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity -238,638
Financial Income 17,384
Financial Expenses -48,379
Income Before Income Tax and Social Contribution -269,633
Income and social contribution taxes - current 3,850
Income Tax and Social Contribution - Deferred 123,824
Effect profit from discontinued operation 0
Net Income -141,959
Recurring Net Income 151,269
Recurring EBITDA 236,836
EBITDA Margin 18.7 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza